drugset / Trial / NCT03891706
Individualized Tumor Specific TCR- T Cells in the Treatment of Advanced Solid Tumors
Phase 1
Recruiting
30 enrolled
Guangzhou FineImmune Biotechnology Co., LTD.
Sun Yat-Sen University Cancer Center · collab
NaSingle-groupOpen-labelTreatment
Summary
The primary purpose of this study is to evaluate the safety of the tumor-specific TCR-T cells in the treatment of advanced Solid Tumor . The secondary purpose of this study is to preliminarily showed the effect of TCR-T cells in the treatment of advanced Solid Tumor .
Timeline
- Start
- 2019-01-08
- Primary completion
- 2025-10-01
- Completion
- 2025-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TCR-T cells | Cell therapy | 5e+08 cells | Intravenous |
| Subject | TCR-T cells | Cell therapy | 5e+09 cells | Intravenous |
| Background | aldesleukin | Protein / enzyme biologic | 3e+06 iu | Intravenous |